Navigation Links
CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
Date:8/27/2007

blation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com

Forward Looking Statements

The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements related to the Company's lead time over other companies conducting atrial fibrillation ablation pivotal trials, ability of obtain FDA approval for and commercialize its product for the treatment of atrial fibrillation and its timing for doing so, including its timing for the filing the related PMA, and ability to, and the benefits from, placing its systems in high volume ablation centers in the U.S., all of which are prospective. Such statements are only predictions and reflect CryoCor's expectations and assumptions as of the date of this press release based on currently available operating, financial, and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks involved with CryoCor's ability to obtain regulatory approval in the United States for its cryoablation system for use in treating atrial fibrillation within its anticipated timeframes, if at all; risks associated with the Company's ability to submit a PMA for atrial fibrillati
'/>"/>

SOURCE CryoCor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Celsion Completes Enrollment in Phase I Liver Cancer Study
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... immunotherapies, announced today that members of its leadership team ... September, including: , First World Congress ... and Food & Environmental Technologies; Portoroz, Slovenia ... Global Investment Conference; New York, NY ...
(Date:9/2/2015)... 2, 2015 The acute coronary syndrome (ACS) ... and hundreds of generics. While generic ACS drugs currently ... is expected to increase to more than 60 percent ... launch of novel pipeline products between 2015 and 2019. ... in terms of revenues, driven primarily by incidence rates ...
(Date:9/1/2015)... and BEDFORD, Mass. , Sept. 1, ... is investigating whether certain officers and directors ... Exchange Act of 1934.  ConforMIS is a medical technology ... develop, manufacture, and sell joint replacement implants that are ... anatomy. View this press release on the ...
Breaking Medicine Technology:OncoSec to Present at Scientific and Investment Conferences in September 2OncoSec to Present at Scientific and Investment Conferences in September 3OncoSec to Present at Scientific and Investment Conferences in September 4OncoSec to Present at Scientific and Investment Conferences in September 5Branded Acute Coronary Syndrome Therapies to Grab Market Share from Generic Drugs Globally 2Branded Acute Coronary Syndrome Therapies to Grab Market Share from Generic Drugs Globally 3Robbins Arroyo LLP Is Investigating the Officers and Directors of ConforMIS, Inc. (CFMS) on Behalf of Shareholders 2
... ANGELES--(BUSINESS WIRE)--July 8, 2007 - Cougar Biotechnology,Inc. (OTCBB:CGRB) ... data on the Company's prostate cancer drug candidate ... for,Medical Oncology (ESMO) Conference, which is currently taking ... two oral and,poster presentations on Sunday, July 8, ...
... July 09, 2007 /PRNewswire-FirstCall/ - YM,BioSciences Inc. ... commercializes differentiated products for patients worldwide,today announced ... Kinki,University School of Medicine and Kyoto University ... for Molecular Target Therapy of,Cancer held on ...
Cached Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy 2YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy 3YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy 4
(Date:9/2/2015)... ... , ... Every year at this time, students prepare to go back to ... face the academic workload confronting them. They just don’t have the skills needed to ... teach students how to study. , “Bankers bank. Salesmen sell. Teachers teach. The job ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... announces Hand Free Pocket Cop, a safety invention that protects people from crime ... worth $31 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:9/2/2015)... ... , ... Ovarian cancer continues to be the deadliest of all gynecologic cancers. ... her lifetime is approximately 1 in 75. This year it is estimated that approximately ... , There is no test to detect ovarian cancer. A Pap test does ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... the pioneer in marine cosmetics introduces PIONNIÈRE XMF Perfection Youth Rich Cream ... cream combines breakthrough biotechnological anti-aging power with a lipid-replenishing marine oil for intense ...
(Date:9/2/2015)... ... September 02, 2015 , ... Canopy Partners, a North Carolina ... Inc. 5000 List, an independent ranking of the fastest- growing private companies ... this achievement puts Canopy in rarefied company. Over the years, this elite group ...
Breaking Medicine News(10 mins):Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 4Health News:Canopy Partners Named to 2015 Inc. 5000 Fastest Growing Companies List 2
... groups were thought to be rare, but recent studies ... the thin beauty ideal. As a result, experts expect ... ethnic groups. It is also suspected that eating disorders ... boys. Although research has shown that eating disorders ...
... of the Charmin Restrooms to ... Times Square This Holiday Season, NEW YORK, Nov. ... free, fully-staffed public restrooms,in New York City as the Charmin(R) Restrooms ... Shannon will inaugurate the stalls,with the ceremonial "first flush" and ribbon ...
... Family Caregiver,s Month; Announces Availability ... More than 34 Million Caregivers, PALO ALTO, Calif., Nov. ... proud to support the more than 34 million,Americans caring for ... availability of its website. Designed to give caregivers the ...
... Flow Cytometry Portfolio Targeted at Fast Growing ... ... Nov. 19, Beckman Coulter, Inc. (NYSE: BEC ), a leading,developer ... A/S, a world leader in cancer diagnostics,announced today that Beckman Coulter ...
... REDWOOD CITY, Calif., Nov. 19 People grow ... is no different. SleepQuest, the leader in,at-home diagnostic ... growing pains which accompany rapid growth by moving ... INC. Magazine,s 5000 Fastest Growing Private,Companies in America, ...
... GNC is joining St. Jude Children,s,Research Hospital as ... is the fourth year for the national campaign and ... in the effort. Thanks and Giving was created ... Thomas and her siblings, Terre and Tony,Thomas, the children ...
Cached Medicine News:Health News:Eating disorders in adolescents 2Health News:Eating disorders in adolescents 3Health News:Video: Charmin's Gift That Keeps on Giving! 2Health News:Resource to Help Care for Aging Parents Now Available Nationwide 2Health News:Resource to Help Care for Aging Parents Now Available Nationwide 3Health News:Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From Dako 2Health News:Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From Dako 3Health News:SleepQuest Continues Growth, Moves Headquarters 2Health News:GNC Joins St. Jude Children's Research Hospital(R) to Kick Off Fourth Annual Thanks And Giving(R) Campaign, Asking America to Help Save Children's Lives While Shopping for the Holidays 2Health News:GNC Joins St. Jude Children's Research Hospital(R) to Kick Off Fourth Annual Thanks And Giving(R) Campaign, Asking America to Help Save Children's Lives While Shopping for the Holidays 3
Expressions lets you change your eye color with lenses that offer incredible comfort and outstanding vision quality. Expression color lenses use a technologically advanced tinting process to produce ...
Modern, innovative and quick Intense Pulsed Light system. The Flash 1 is light and very compact, thus easily portable. Available in two different colors....
... for the physician who wishes to offer ... of clinical applications. The innovative cooled Nd:YAG ... treaent of deeper lying veins. The IPL ... and pigmented lesions, including IPL Skin Treaents ...
Available in Purple, orange, dark blue, yellow, gray, royal blue, green and light blue colors....
Medicine Products: